Astrazeneca PLC (NYSE:AZN) was downgraded by investment analysts at Liberum Capital from a “buy” rating to a “hold” rating in a report released on Thursday, MarketBeat reports.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Barclays PLC reaffirmed an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Morgan Stanley downgraded shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Pareto Securities raised shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, Investec raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $33.60.

Astrazeneca PLC (NYSE AZN) traded down 0.28% during trading on Thursday, reaching $32.53. 3,100,668 shares of the company were exchanged. The stock has a market capitalization of $82.37 billion, a price-to-earnings ratio of 21.34 and a beta of 0.74. The firm’s 50 day moving average price is $30.20 and its 200-day moving average price is $31.74. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The company’s revenue was down 9.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.83 earnings per share. On average, equities research analysts predict that Astrazeneca PLC will post $1.90 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Astrazeneca PLC (AZN) Stock Rating Lowered by Liberum Capital” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/16/astrazeneca-plc-azn-stock-rating-lowered-by-liberum-capital.html.

Several hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP increased its position in shares of Astrazeneca PLC by 7.9% in the first quarter. Wellington Management Group LLP now owns 63,250,780 shares of the company’s stock worth $1,969,630,000 after purchasing an additional 4,605,694 shares during the last quarter. Bank of America Corp DE increased its position in shares of Astrazeneca PLC by 29.5% in the first quarter. Bank of America Corp DE now owns 45,744,976 shares of the company’s stock worth $1,424,498,000 after purchasing an additional 10,414,969 shares during the last quarter. Primecap Management Co. CA increased its position in shares of Astrazeneca PLC by 32.1% in the first quarter. Primecap Management Co. CA now owns 34,310,950 shares of the company’s stock worth $1,068,443,000 after purchasing an additional 8,330,675 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Astrazeneca PLC by 476.9% in the second quarter. Fisher Asset Management LLC now owns 11,081,856 shares of the company’s stock worth $377,780,000 after purchasing an additional 9,160,764 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Astrazeneca PLC by 287,844.0% in the first quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock worth $215,198,000 after purchasing an additional 6,908,257 shares during the last quarter. Institutional investors own 14.18% of the company’s stock.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.